STEP I: Patients with monoclonal gammopathy of undetermined significance or asymptomatic multiple myeloma are not eligibleXx_NEWLINE_xXHistologically confirmed diagnosis of symptomatic multiple myeloma; relapsed disease is myeloma that has previously responded to prior therapy (MR or better) and subsequently progressedXx_NEWLINE_xXRelapsed or relapsed/refractory multiple myeloma (MM) with progressive disease (PD) parameters according to International Myeloma Working Group (IMWG) criteria\r\n* Refractory is defined as experiencing less than minimal response to or PD within 60 days of the most recent line therapy\r\n* Relapsed is defined as patients requiring salvage therapy for PD who are not refractory to the most recent line of therapyXx_NEWLINE_xXDiagnosis of multiple myeloma (MM) with relapsed and/or refractory disease. Participants must have received at least 3 prior lines of therapy. Participants must have previously received all of the following therapies and must be refractory to the last line of therapy prior to entering the study:Xx_NEWLINE_xXParticipant has relapsed or refractory multiple myeloma with documented evidence of progression that occurred during or after the participant's last treatment regimen based on investigator's determination of International Myeloma Working Group (IMWG) criteria.Xx_NEWLINE_xXParticipant has received previous multiple myeloma treatment as defined in the protocol for Part 1 and Part 2 of this study.Xx_NEWLINE_xXKnown meningeal involvement of multiple myeloma.Xx_NEWLINE_xXMales or females with multiple myeloma who have exhausted available standard therapies.Xx_NEWLINE_xXAnti-myeloma treatment within 2 weeksXx_NEWLINE_xXParticipants must have relapsed or refractory (R/R) multiple myeloma (MM) for which no established therapy for MM is appropriate and available or be intolerant to those established therapiesXx_NEWLINE_xXPatients with relapse/ refractory multiple myelomaXx_NEWLINE_xXHistologically confirmed Multiple Myeloma prior to enrolment and randomization.Xx_NEWLINE_xXHistologically confirmed diagnosis of secretory multiple myeloma (must have measurable M protein in serum or urine) with at least one of the following:Xx_NEWLINE_xXprimary refractory myeloma (PRMM): subjects who have never achieved the minimal response or better to prior therapy ORXx_NEWLINE_xXSubjects with only plasmacytomas, plasma cell leukemia, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), non-secretory myeloma or primarily amyloidosis.Xx_NEWLINE_xXA prior diagnosis of multiple myeloma with documented disease progression requiring further treatment at time of screeningXx_NEWLINE_xXHematologic malignancies (including lymphoma, multiple myeloma)Xx_NEWLINE_xXPotential subjects with evidence of progressive disease as per International Myeloma Working Group (IMWG) criteriaXx_NEWLINE_xXWaldenstrom’s macroglobulinemia or immunoglobulin (Ig)M myelomaXx_NEWLINE_xXPatients must have a confirmed biopsy diagnosis of a multiple myelomaXx_NEWLINE_xXDiagnosis of multiple myeloma (MM) and documentation of treatmentXx_NEWLINE_xXHistologically or cytologically confirmed multiple myelomaXx_NEWLINE_xXPrevious diagnosis of multiple myeloma based on standard criteria; tests need not be performed within 30 days of registrationXx_NEWLINE_xXUse of any myeloma-specific therapy within 21 days of the MILs collectionXx_NEWLINE_xXMyeloma specific therapy with a minimum of 3 cyclesXx_NEWLINE_xXRelapsed and relapsed/refractory multiple myeloma requiring systemic therapyXx_NEWLINE_xXWaldenstrom’s macroglobulinemia or immunoglobulin M (IgM) myelomaXx_NEWLINE_xXCytopathologically or histologically confirmed dx of multiple myelomaXx_NEWLINE_xXIneligible disease sites include the following\r\n* Lymphoma\r\n* Leukemia\r\n* Multiple myeloma\r\n* Primary CNS\r\n* Peritoneal carcinomatosis \r\n* Colon cancer with resectable liver-only lesionsXx_NEWLINE_xXB-CLL or recurrent or refractory B-cell lymphoma (or other B-cell neoplasm) or multiple myeloma monoclonal for Kappa-light chainXx_NEWLINE_xXMultiple myeloma diagnosed according to the International Myeloma Working Group (IMWG) diagnostic criteriaXx_NEWLINE_xXDiagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG])Xx_NEWLINE_xXAny prior therapy for symptomatic multiple myeloma or smoldering multiple myeloma should also be excluded, including prior use of IMIDs, proteasome inhibitors, or CD138 inhibitors; prior therapy for smoldering multiple myeloma with agents that are not therapeutically active against MM is not an exclusion criterionXx_NEWLINE_xXIs in need of additional myeloma therapy as determined by the investigator.Xx_NEWLINE_xXHas previously received at least 3 lines of myeloma therapy.Xx_NEWLINE_xXDiagnosis of advanced solid tumor cancer, lymphoma, or myeloma (no time restrictions or limitations) -OR- diagnosis of early stage solid tumor cancer, lymphoma, or myeloma <= 12 months prior to study enrollmentXx_NEWLINE_xXMalignant melanoma, papillary thyroid cancer, colorectal cancer, or hematologic malignancy including multiple myelomaXx_NEWLINE_xXPatients with high risk multiple myeloma (criterion 3a above) in very good partial response (VGPR) or better at the time of enrollment with at most 1 prior progression within 18 months from initiation of systemic anti-myeloma therapy, which may include single or planned tandem autologous HSCT; orXx_NEWLINE_xXPatients with standard risk multiple myeloma in VGPR or better at the time of enrollment with 1 prior progression within 18 months from a single or planned tandem autologous HSCT; orXx_NEWLINE_xXSubjects must have documented evidence of progressive disease according to the IMWG uniform response criteria following the last multiple myeloma treatment.Xx_NEWLINE_xXIgA, IgD, IgE, IgM multiple myeloma: serum M-protein level ?0.5 g/dL (measured by PEP).Xx_NEWLINE_xXMultiple myeloma diagnosed according to standard criteria either currently or at the time of initial diagnosisXx_NEWLINE_xXmultiple myeloma as per IMWG 2014 definitionXx_NEWLINE_xXprimary refractory myelomaXx_NEWLINE_xXRelapsed multiple myeloma in patients that have been treated previously with autologous hematopoietic stem cell transplantation (auto-HCT), bortezomib and an imunomodulatory agent, AND with at least one of the following high-risk criteria \r\n* High-risk multiple myeloma defined by cytogenetic or fluorescence in situ hybridization (FISH) detection of any one or more of the following: \r\n** Deletion 17p \r\n** Translocation t(4;14) \r\n** Translocation t(14;16) \r\n** Translocation t(14;20)\r\n** Chromosome 1q gain \r\n** Chromosome 1p deletion\r\n** Deletion 13q by conventional karyotyping (FISH only not acceptable)\r\n** Hypodiploidy\r\n* High-risk gene expression profiling (GEP) at the time of relapse (by Signal Genetics Myeloma Prognostic Risk Signature [MyPRS] score)\r\n* Beta-2 (B2) microglobulin > 5.5 mg\r\n* Plasmablastic morphology (> 2%)\r\n* Relapsed plasma cell leukemiaXx_NEWLINE_xXmultiple myelomaXx_NEWLINE_xXMen and women, 18 years or older, with advanced, relapsed or refractory solid tumors, Multiple Myeloma (MM) or non-Hodgkin's lymphoma (NHL) in Part A. In Part B, relapsed or refractory CD20-positive NHL subjects only.Xx_NEWLINE_xXAdult male or female participants 18 years or older with a confirmed diagnosis of symptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria.Xx_NEWLINE_xXMultiple myeloma that has relapsed after, or was not responsive to, initial therapy.Xx_NEWLINE_xXPatients may have had multiple primary melanomas.Xx_NEWLINE_xXPatient must have relapsed or refractory myeloma that fits or did fit International Myeloma Working Group (IMWG) diagnostic criteria for symptomatic myeloma (although new or worsening end organ damage is not required to be eligible) as defined below:\r\n* Presence of clonal bone marrow plasma cells\r\n* Presence of serum and/or urinary measurable monoclonal protein or light chains\r\n* Evidence of any end organ damage criteria listed below (at any time) attributed to the patient’s myeloma:\r\n** Hypercalcemia: serum calcium > 11.5 mg/dL or\r\n** Renal insufficiency: serum creatinine > 2 mg/dL\r\n** Anemia > 2 g/dL below the lower limit of normal or a hemoglobin value < 10 g/dL\r\n** Bone lesions: lytic lesions, severe osteopenia or pathologic fracturesXx_NEWLINE_xXSymptomatic multiple myeloma, International Staging System (ISS) stages I-III, within 12 months of starting therapyXx_NEWLINE_xXCompletion of induction therapy with very good partial response (VGPR), or better, by International Myeloma Working Group (IMWG) criteriaXx_NEWLINE_xXCOHORT A: multiple myelomaXx_NEWLINE_xXPrior cytotoxic chemotherapy or corticosteroids for the treatment of multiple myeloma; NOTE: prior corticosteroid use for the treatment of non-malignant disorders is permittedXx_NEWLINE_xXPatients must have histologically or cytologically confirmed smoldering multiple myeloma confirmed by the Laboratory of Pathology, National Cancer Institute (NCI) or the Department of Laboratory Medicine, clinical center (CC), as needed, and based on the International Myeloma Working Group CriteriaXx_NEWLINE_xXMultiple myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or beta-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapyXx_NEWLINE_xXRelapsed, relapsed and refractory or refractory multiple myeloma patients who have received > 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD28 monoclonal antibodyXx_NEWLINE_xXReceived systemic treatment for multiple myeloma, including immunotherapy, within 14 days prior to initiation of study proceduresXx_NEWLINE_xXDiagnosis of relapsed, symptomatic multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria for multiple myelomaXx_NEWLINE_xXMyeloma disease that is refractory to ixazomib treatmentXx_NEWLINE_xXA prior diagnosis of multiple myeloma with documented disease progression in need of treatment at time of screeningXx_NEWLINE_xXPathologically confirmed diagnosis of multiple myeloma who are transplant eligible and have received any prior induction therapy (with or without maintenance)Xx_NEWLINE_xXAny previous ASCT for multiple myeloma (MM)Xx_NEWLINE_xXExhibiting clinical signs of meningeal involvement of multiple myelomaXx_NEWLINE_xXPatients with multiple myeloma in first relapse (or who are primary refractory) following treatment with a bortezomib-containing regimen (excluding prior treatment with ixazomib)Xx_NEWLINE_xXPatient’s multiple myeloma cells are positive for CD28 or CD86 expression by flow cytometry or immunohistochemistry (in any proportion)Xx_NEWLINE_xXPatients with clinical relapse/progression as per the International Myeloma Working Group (IMWG) uniform criteria defined as one or more of the following criteria:\r\n* Development of new soft tissue plasmacytomas or bone lesions (osteoporotic fractures do not constitute progression)\r\n* Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and >= 1 cm) increase as measured serially of the measurable lesion\r\n* Hypercalcemia (> 11 mg/dL)\r\n* Decrease in hemoglobin of >= 2 g/dL not related to therapy or other non-myeloma-related conditions\r\n* Rise in serum creatinine by 2 mg/dL or more from the start of the therapy and attributable to myeloma\r\n* Hyperviscosity related to serum paraproteinXx_NEWLINE_xXDocumented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteriaXx_NEWLINE_xXParticipants with measurable multiple myeloma who have progressed on, or could not tolerate, all available established therapiesXx_NEWLINE_xXPatients must meet the criteria for symptomatic multiple myeloma prior to initiating systemic anti-myeloma treatment.Xx_NEWLINE_xXPatients must have received < 2 cycles of systemic anti-myeloma therapy.Xx_NEWLINE_xXPatients with histologically-confirmed symptomatic multiple myeloma or AL amyloidosis undergoing autologous hematopoietic cell transplantation (HCT) with melphalan 140 or 200 mg/m^2Xx_NEWLINE_xXEvidence of a response (Partial response [PR] or better based on investigator's determination of response by international myeloma working group [IMWG] criteria) to at least 1 prior treatment regimenXx_NEWLINE_xXDocumented multiple myeloma as defined by the criteria below:Xx_NEWLINE_xXMultiple myeloma diagnosis according to the IMWG diagnostic criteriaXx_NEWLINE_xXInternational Staging System (ISS) stage I-III multiple myeloma that has progressive, relapsed, or refractory diseaseXx_NEWLINE_xXRelapsed and/or refractory myeloma; there is no minimum or maximum number of previous therapies that a patient may have received previously before being put on the current trialXx_NEWLINE_xXSmoldering (asymptomatic) multiple myelomaXx_NEWLINE_xXHistologically- or cytologically-confirmed relapsed or refractory multiple myeloma (MM) with measurable diseaseXx_NEWLINE_xXDiagnosis of multiple myeloma refractory to or relapsed after >= 1 line of prior therapy (International Myeloma Working Group [IMWG] criteria)Xx_NEWLINE_xXConcurrent multiple myeloma (defined according to 2015 International Myeloma Working Group [IMWG] guidelines)Xx_NEWLINE_xXMultiple myeloma, solitary plasmacytoma, or primary malignant lesions in the index vertebra or boneXx_NEWLINE_xXDiagnosis of newly diagnosed multiple myeloma with indication for initiation of therapyXx_NEWLINE_xXPatients must have been previously diagnosed with histologically or cytologically confirmed symptomatic multiple myeloma, which require the presence of all three of the following International Myeloma Working Group criteria, except as noted:\r\n* Clonal bone marrow plasma cells >= 10%\r\n* A monoclonal protein in either serum or urine\r\n* Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder (to include one of the following)\r\n** Hypercalcemia (corrected calcium > 2.75 mmol/L or 11.5 mg/dL); OR\r\n** Renal insufficiency attributable to myeloma (serum creatinine > 1.9 mg/dL); OR\r\n** Anemia; normochromic, normocytic with a hemoglobin value >= 2 g/dL below the lower limit of normal, or a hemoglobin or < 10 g/dL; OR\r\n** Bone lytic lesions (magnetic resonance imaging [MRI], computed tomography [CT] or positron emission tomography [PET]/CT with > 1 focal lesions >= 5 mm in size), severe osteopenia or pathologic fractures\r\n* Patients with a biopsy-proven plasmacytoma and either a serum or urine monoclonal protein will also be considered to have met the diagnostic criteria for multiple myeloma in the absence of clonal marrow plasmacytosis of >= 10%\r\n* Patient with bone marrow plasma cells of >= 60% or serum free light chain ratio of >= 100 will also be considered to have met the diagnostic criteria for multiple myelomaXx_NEWLINE_xXWorsening urinary paraproteinemia will be considered in the context of International Myeloma Working Group (IMWG) disease response criteria on a monthly basis; any patient with urinary protein (otherwise unrelated to urinary myeloma associated monoclonal [M]-protein) with excretion > 3.5 g/day will be considered to have developed nephrotic-range proteinuria, and will be taken off studyXx_NEWLINE_xXMust have a confirmed diagnosis of multiple myeloma (MM) requiring therapy according to International Myeloma Working Group (IMWG) criteria.Xx_NEWLINE_xXDocumented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteriaXx_NEWLINE_xXMeasurable multiple myeloma that is relapsed or refractory to established therapies with known clinical benefit in relapsed/refractory multiple myeloma or be intolerant of those established multiple myeloma therapies, and a candidate for JNJ-64007957 treatment in the opinion of the treating physician. Prior lines of therapy must include a proteasome inhibitor and an immunomodulatory drug in any order during the course of treatment. Participants who could not tolerate a proteasome inhibitor or immunomodulatory drugs are allowedXx_NEWLINE_xXPatients with a confirmed diagnosis of multiple myeloma who have received two or more lines of therapy including an IMiD and PI, and are relapsed and/or refractory to their most recent line of therapy. Patients who have received a prior autologous bone marrow transplant and otherwise meet the inclusion criteria are eligible for this study.Xx_NEWLINE_xXHistologically confirmed diagnosis of multiple myelomaXx_NEWLINE_xXPrior therapy for AL amyloidosis or multiple myeloma including medications that target CD38, with the exception of 160 mg dexamethasone (or equivalent corticosteroid) maximum exposure prior to randomizationXx_NEWLINE_xXFOR MULTIPLE MYELOMA ONLY: Obtained =< 14 days prior to registration: Platelet (PLT) >= 100,000/uLXx_NEWLINE_xXFOR MULTIPLE MYELOMA ONLY: Obtained =< 14 days prior to registration: Hemoglobin >= 8.5 g/dlXx_NEWLINE_xXMULTIPLE MYELOMA ONLYMultiple : >= 15% plasmas cells or plasmacytoma > 5 cm in largest diameterXx_NEWLINE_xXDiagnosis\r\n* Phase I: confirmed diagnosis of relapsed or refractory multiple myeloma\r\n* Phase II: confirmed diagnosis of active multiple myeloma and must be newly diagnosed\r\n* NOTE: all tests for establishing disease status must be completed =< 28 days prior to registrationXx_NEWLINE_xXRelapsed multiple myeloma that is chemotherapy sensitive and has failed or ineligible for an autologous transplantXx_NEWLINE_xXDiagnosis of symptomatic multiple myeloma as per current International Myeloma Working Group (IMWG) uniform criteria prior to initial treatmentXx_NEWLINE_xXWaldenstrom’s macroglobulinemia or IgM myelomaXx_NEWLINE_xXPatients with poor prognosis multiple myeloma by cytogenetics del13, del 17p, t(4;14) or t(14;16) or hypodiploidy, with advanced disease (stage >= 2) and /or relapsed after autologous stem cell transplantXx_NEWLINE_xXPatients must have histologically confirmed smoldering multiple myeloma (SMM) based on the following criteria; both criteria must be met: (a) serum monoclonal protein (IgG or IgA) >= 3 g/dL or urinary monoclonal protein >= 500 mg per 24 hours and/or clonal bone marrow plasma cells 10-60% (b) absence of myeloma defining events or amyloidosisXx_NEWLINE_xXAdditionally, patients must meet criteria for high risk of progression to multiple myeloma by PETHEMA CRITERIA (patients must have at least 2 risk factors present)\r\n* 1. >= 95% abnormal plasma cells/total plasma cells in bone marrow compartment (this is measured as a percentage of the total abnormal versus normal plasma cells in the bone marrow compartment using standard flow cytometry of the bone marrow aspirate; having >= 95% abnormal plasma cells/total plasma cells constitutes a risk factor for progression to multiple myeloma by PETHEMA criteria) \r\n* 2. Immunoparesis (this term refers to the patient having low uninvolved immunoglobulins in peripheral blood, for example if a patient has IgA smoldering multiple myeloma, then either having a low IgM and/or low IgG will qualify as a risk factor for progression to multiple myeloma)\r\n** 2 of 2 risk factors: high risk for progression at a rate of 72% at 5 yearsXx_NEWLINE_xXPrior or concurrent systemic treatment for SMM; b) bisphosphonates are permitted, including pamidronate, zoledronic acid, alendronate, ibandronate, risedronate; c) treatment with corticosteroids is not permitted, unless the patient is on a stable chronic dose of inhaled steroids to treat respiratory diseases or on stable chronic steroid replacement therapy for endocrinology disorders; d) radiotherapy is not permitted, e) prior treatment for smoldering multiple myeloma with chemotherapy agents approved for the treatment of multiple myeloma or CD38 drugs is not permittedXx_NEWLINE_xXHas received prior anti-myeloma therapy of any typeXx_NEWLINE_xXHistologic and serologic findings, reviewed at Memorial Sloan Kettering Cancer Center (MSKCC), confirming the diagnosis of multiple myeloma or AL amyloidosis; standard diagnostic criteria for multiple myeloma will be used, as per the International Myeloma Foundation consensus guidelinesXx_NEWLINE_xXPrimary lesions with the following histologies: small cell carcinoma, germ-cell tumors, lymphoma, leukemia, and multiple myelomaXx_NEWLINE_xXSubjects must have a confirmed diagnosis of active multiple myeloma according to IMWG criteria; in addition, subjects must have “high-risk” multiple myeloma according to one of the following criteria:\r\n* Any of the following high-risk cytogenetic features, documented by fluorescence in situ hybridization (FISH) or metaphase karyotyping: deletion 17p, t(4;14), t(14;16), t(14;20)\r\n* Standard-risk cytogenetics but elevated lactate dehydrogenase (LDH) and beta-2-microglobulin > 5.5 mg/L (i.e., Revised International Staging System [R-ISS] stage III)Xx_NEWLINE_xXAt time of enrollment, subjects must be within 9 months of initiation of systemic therapy for multiple myelomaXx_NEWLINE_xXPatients with histologically confirmed multiple myelomaXx_NEWLINE_xXReceived less than 4 lines of anti-myeloma therapyXx_NEWLINE_xXNon-secretory multiple myelomaXx_NEWLINE_xXMultiple myeloma: stage II or III, symptomatic, secretory multiple myeloma requiring treatmentXx_NEWLINE_xXRESEARCH SAMPLE COLLECTION: Histologically confirmed diagnosis of multiple myelomaXx_NEWLINE_xXHistologically confirmed diagnosis of multiple myelomaXx_NEWLINE_xXMeeting the criteria for symptomatic multiple myeloma (hypercalcemia renal [kidney] impairment, anemia, bone lesions \[CRAB]” criteria) before the initiation of systemic chemotherapyXx_NEWLINE_xXRelapsed multiple myeloma that is chemotherapy sensitive and has failed or ineligible for an autologous transplantXx_NEWLINE_xXPrimary tumors of radiosensitive histology (lymphoma, multiple myeloma, small cell carcinoma, germ cell tumors), as conventional radiation is likely to be effective in such casesXx_NEWLINE_xXPatient must have relapsed and symptomatic multiple myelomaXx_NEWLINE_xXPatients who have received > 3 prior treatment regimens for multiple myelomaXx_NEWLINE_xXMultiple myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or beta-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapyXx_NEWLINE_xXMultiple myeloma progressive on salvage chemotherapyXx_NEWLINE_xXSubjects with symptomatic multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria who are receiving or have completed induction chemotherapy, who have achieved at least a partial response (PR) on most recent therapy by IMWG criteria, and are eligible for auto-SCT for consolidation; a specific induction regimen is not dictated for this protocol, however, the induction regimen must not have contained melphalan (L-PAM, Alkeran)Xx_NEWLINE_xXMultiple myeloma specific:\r\n* Confirmed evidence of disease progression from immediately prior multiple myeloma (MM) therapy or refractory to the immediately prior treatment\r\n* Measurable disease M protein component in serum (at least 0.5 g/dL) and/or urine (if present), (>=0.2 g excreted in a 24 hour collection sample)\r\n* Subjects with free light chain only disease are excludedXx_NEWLINE_xXSubjects must have a confirmed prior diagnosis of active MM as defined by the International Myeloma Working Group (IMWG) criteriaXx_NEWLINE_xXHistologies of myeloma or lymphomaXx_NEWLINE_xXPrimary tumor histology of lymphoma, leukemia, multiple myeloma or germ cell tumorXx_NEWLINE_xXHistologically confirmed diagnosis of symptomatic multiple myeloma; (patients with multiple myeloma with secondary amyloidosis are eligible)Xx_NEWLINE_xXReceived at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-16 months of the first dose of initial therapyXx_NEWLINE_xXAdministration or planned administration of any other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy which would be considered a treatment of multiple myeloma until day +28 post-transplant through discontinuation from study; patients may be on corticosteroids if they are being given for disorders other than multiple myeloma (e.g., adrenal insufficiency, rheumatoid arthritis, etc.)Xx_NEWLINE_xXConcurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma and secondary amyloidosis)Xx_NEWLINE_xXMeasurable relapsed or refractory myeloma as defined by the International Myeloma Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI and an IMiD.Xx_NEWLINE_xXNon-secretory multiple myelomaXx_NEWLINE_xXRecent history of other (non multiple myeloma) cancerXx_NEWLINE_xXPatients must have a diagnosis of multiple myelomaXx_NEWLINE_xXPrimary lesion with radiosensitive histology that includes the following: small cell carcinoma, germ cell tumors, lymphoma, leukemia, or multiple myelomaXx_NEWLINE_xXMultiple myeloma\r\n* Relapse/progression after autologous HSCT\r\n* Plasma cell leukemia\r\n* Adverse cytogenetics: e.g. del(13q) or 11q translocation\r\n* At the time of enrollment, multiple myeloma (MM) must be in complete remissionXx_NEWLINE_xXPatients with newly diagnosed multiple myeloma who have at least a partial response after induction therapy based on the International Working Group (IWG) Uniform Response CriteriaXx_NEWLINE_xXPROCUREMENT: Diagnosis of myeloma after receiving at least one treatment regimenXx_NEWLINE_xXPatients with multiple malignancies remain eligibleXx_NEWLINE_xXDiagnosis of symptomatic multiple myeloma (MM)Xx_NEWLINE_xXPatients should have received the autologous SCT within 12 months of their diagnosis of myeloma to be eligible for the studyXx_NEWLINE_xXConcurrent chemotherapy, radiotherapy, or any ancillary therapy for treatment of multiple myeloma; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXPrimary tumor histology of lymphoma, leukemia, multiple myeloma or germ cell tumorXx_NEWLINE_xXSymptomatic multiple myeloma, International Staging System (ISS) stage 1-3 with confirmed diagnosis of multiple myeloma at Memorial Sloan-Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXCytopathologically or histologically confirmed diagnosis of multiple myelomaXx_NEWLINE_xXRecipients of first/second ASCT for the treatment of hematologic malignancies (multiple myeloma, Hodgkin's and non Hodgkin's lymphoma)Xx_NEWLINE_xXSymptomatic multiple myeloma of any subtype in any disease stage, providing the patient does not have smoldering myeloma, and otherwise met standard criteria (hypercalcemia, renal dysfunction, anemia and/or bone lesions – CRAB criteria) for induction therapyXx_NEWLINE_xXRefractory or relapsed and refractory multiple myelomaXx_NEWLINE_xXDiagnosis of multiple myeloma (MM) with deletion 17p (del17p) or monosomy 17 by fluorescence in situ hybridization (FISH) who have received at least one line of therapyXx_NEWLINE_xXRecipients must have histopathologically confirmed diagnosis of multiple myelomaXx_NEWLINE_xXMultiple myeloma with disease in the following categories:\r\n* Patients with relapsed multiple myeloma following autologous stem cell transplantation who have achieved at least partial response following additional chemotherapy\r\n* Patients with high risk cytogenetics at diagnosis must have achieved at least a partial response following autologous stem cell transplantation; patients must have complex karyotype, del17p, t4;14 and/or t14;16 by fluorescent in situ hybridization (FISH) and/or del13 by karyotypingXx_NEWLINE_xXMultiple Myeloma (> CR2, > PR2) or after initial therapy if no prior PR: recent chemotherapy responsivenessXx_NEWLINE_xXMultiple myeloma beyond PR2; patients with chromosome 13 abnormalities, first response lasting less than 6 months, or beta-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapyXx_NEWLINE_xXMultiple myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or beta-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapyXx_NEWLINE_xXPatients must have one of the following diagnoses of multiple myeloma (MM) or primary/secondary myelofibrosis (MF)Xx_NEWLINE_xXPatients must have a known diagnosis of multiple myeloma with evidence of measurable disease, as defined below:Xx_NEWLINE_xXPatient must have achieved MR or better with any anti-myeloma therapy (ie, primary refractory disease is not eligible).Xx_NEWLINE_xXMust have a diagnosis of a MM using current International Myeloma Working Group (IMWG) diagnostic criteria and have received 1 prior line of therapy.Xx_NEWLINE_xXCriteria 1 Relapsed or progressive multiple myeloma after last treatmentXx_NEWLINE_xXIgG multiple myeloma: serum monoclonal paraprotein (M-protein) levelXx_NEWLINE_xXIgA, IgD, IgE multiple myeloma: serum M-protein level ? 0.5 g/dL,Xx_NEWLINE_xXCriteria 2 Multiple myeloma of IgM subtypeXx_NEWLINE_xXSubject has histologically confirmed multiple myeloma that has never before been treatedXx_NEWLINE_xXSubject has previously been treated for multiple myelomaXx_NEWLINE_xXDiagnosis of multiple myeloma as per International Myeloma Working Group (IMWG) uniform criteriaXx_NEWLINE_xXRelapsed/refractory multiple myeloma with progressive disease at study entryXx_NEWLINE_xXPatient must have a diagnosis of multiple myeloma and have relapsed or relapsed/refractory disease.Xx_NEWLINE_xXPatient has smoldering multiple myeloma or monoclonal gammopathy of unknown significance (MGUS).Xx_NEWLINE_xXPatient received chemotherapy or other anti-cancer therapy that may be active against multiple myeloma within 3 weeks prior to the first dose of PRLX 93936.Xx_NEWLINE_xXPatient is taking any therapy concomitantly that may be active against multiple myeloma.Xx_NEWLINE_xXMultiple myeloma: stage II or III, symptomatic, secretory multiple myeloma requiring treatmentXx_NEWLINE_xXPatient with confirmed multiple myeloma requiring systemic therapy. All three criteria must be met:Xx_NEWLINE_xXPatient with multiple myeloma relapsing according to the International uniform response criteria for multiple myeloma (IMWG 2009/ revised Bladé criteria) to one previous line of treatmentXx_NEWLINE_xXPatient whose disease progressed during or within 60 days of bortezomib treatment or of any other Multiple Myeloma therapyXx_NEWLINE_xXConfirmed relapsed or refractory multiple myeloma after at least two prior lines of therapy.Xx_NEWLINE_xXMultiple myeloma (Eligible patients must have quantifiable M-protein levels present in serum and/or urine)Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of multiple myeloma that is relapsed or relapsed-and-refractory after at least 2 or more prior lines of therapy. Patients must have achieved at least minor response (MR) to at least one prior line of therapyXx_NEWLINE_xXProgressive disease must have occurred either during or subsequent to the patient's last treatment for multiple myeloma prior to the current enrollmentXx_NEWLINE_xXPatient must have substantially recovered from clinically significant toxicities from prior therapies for multiple myelomaXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of MM as defined according to International Myeloma Working Group (IMWG). The subject has undergone stem cell transplant or is considered transplant ineligible and has failed at least 3 prior lines of anti-myeloma treatments, including an anti-CD38 antibody (example [e.g.], daratumumab) alone or in combination, and is refractory to an Immunomodulatory drugs (IMiD) (that is [i.e.], lenalidomide or pomalidomide), and to a proteasome inhibitor (i.e., bortezomib, ixazomib or carfilzomib).Xx_NEWLINE_xXHave confirmed diagnosis of Multiple Myeloma as defined by the IMWG.Xx_NEWLINE_xXDocumented diagnosis of multiple myeloma (MM) based on standard IMWG criteria.Xx_NEWLINE_xXMultiple myeloma meeting the following criteria:Xx_NEWLINE_xXMultiple myeloma with IgM subtypeXx_NEWLINE_xXHistologically confirmed diagnosis of multiple myeloma; (patients with multiple myeloma with secondary amyloidosis are eligible)Xx_NEWLINE_xXReceived at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-13 months of the first dose of initial therapyXx_NEWLINE_xXEvidence of multiple myeloma (MM) disease progression any time prior to enrollment; progression from smoldering to active myeloma is not exclusionaryXx_NEWLINE_xXPatients with multiple myeloma in complete response (CR), partial remission (PR), very good partial remission (VGPR), or symptomatic stable disease (no evidence of progression) including patients with light chain multiple myeloma (MM) detected in the serum by free light chain assay.Xx_NEWLINE_xXRelapsed or refractory multiple myeloma. Participants with primary refractory myeloma only allowed in dose-escalation phase of the study.Xx_NEWLINE_xXDocumented diagnosis of symptomatic multiple myeloma, as defined by the IMWGXx_NEWLINE_xXFor expansion cohorts only: Primary refractory multiple myeloma defined as disease that is non-responsive in participants who have never achieved a minimal response or better with any therapyXx_NEWLINE_xXPlan to receive anti-myeloma therapiesXx_NEWLINE_xXSubjects must have histologically confirmed diagnosis of multiple myelomaXx_NEWLINE_xXPlanned concurrent treatment for multiple myeloma other than bisphosphonatesXx_NEWLINE_xXPatient has been previously diagnosed with multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteriaXx_NEWLINE_xXDiagnosis of multiple myeloma according to International Myeloma Working Group criteria and one of the following:\r\n* Smoldering multiple myeloma (SMM)\r\n* Indolent multiple myeloma (IMM)\r\n* Newly diagnosed multiple myeloma (MM)\r\n* Note: patients with lytic disease and anemia are eligibleXx_NEWLINE_xXPatients must meet established criteria for the diagnosis of multiple myelomaXx_NEWLINE_xXPatients with non-secretory multiple myeloma are not eligibleXx_NEWLINE_xXDiagnosis and previously untreated active multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria for multiple myelomaXx_NEWLINE_xXPrior cytotoxic chemotherapy or corticosteroids for the treatment of multiple myeloma\r\n* NOTE: Prior corticosteroid use for the treatment of non-malignant disorders is permittedXx_NEWLINE_xXFOR PATIENTS WITH MULTIPLE MYELOMA (MM):Xx_NEWLINE_xXDiagnosis of multiple myelomaXx_NEWLINE_xXSymptomatic multiple myeloma requiring treatmentXx_NEWLINE_xXReceived at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-12 months of the first dose of initial therapyXx_NEWLINE_xXEvidence of multiple myeloma disease progression (as defined by International Myeloma Working Group [IMWG]) any time prior to ASCTXx_NEWLINE_xXSmoldering multiple myeloma (MM) not requiring therapyXx_NEWLINE_xXMultiple myeloma progressive on salvage chemotherapyXx_NEWLINE_xXHistologically confirmed diagnosis of multiple myelomaXx_NEWLINE_xXReceived at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-12 months of the first dose of initial therapyXx_NEWLINE_xXConcurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma or secondary amyloidosis)Xx_NEWLINE_xXMULTIPLE MYELOMA CRITERIA:Xx_NEWLINE_xXPatients must have received at least 3 different prior treatment regimens for multiple myelomaXx_NEWLINE_xXPatients must carry a diagnosis of symptomatic multiple myeloma according to international myeloma working group criteria and have relapsed or refractory disease according to international uniform response criteria after at least two prior treatment regimens including a proteasome inhibitor and an immunomodulator (IMiD)Xx_NEWLINE_xXRadiosensitive primary tumor such as small cell lung cancer, germ cell tumors, lymphoma, leukemia, or multiple myelomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed multiple myeloma not otherwise specified (NOS) (10028566)Xx_NEWLINE_xXA diagnosis of multiple myeloma (MM) and documentation of relapsed or relapse/refractory status following at least 2 prior lines of therapyXx_NEWLINE_xXPatients must have a confirmed diagnosis of symptomatic multiple myeloma and must be currently relapsed or refractory; except where otherwise indicated below that assessment is required within 14 days, all tests for establishing disease status must be completed within 28 days prior to registration and documented on the Baseline Tumor Assessment Form for Multiple MyelomaXx_NEWLINE_xXSymptomatic, previously untreated (with exception of corticosteroids) secretory myelomaXx_NEWLINE_xXAny chemotherapy, immunotherapy, biologic, investigational, for treatment of multiple myeloma other than lenalidomide and dexamethasoneXx_NEWLINE_xXPrevious systemic cancer therapy for myelomaXx_NEWLINE_xXDiagnosis of non-secretory myelomaXx_NEWLINE_xXMULTIPLE MYELOMA CRITERIAXx_NEWLINE_xXMultiple myeloma\r\n* Primary treatment failure\r\n* Relapse after autologous SCT or for consolidation after autologous SCT\r\n* Non-CR after salvage regimenXx_NEWLINE_xXParticipants must have documented symptomatic myeloma, with organ damage related to myeloma as defined above with laboratory assessmentsXx_NEWLINE_xXPrior glucocorticosteroid therapy for the treatment of multiple myeloma is not permittedXx_NEWLINE_xXConfirmed diagnosis of active multiple myeloma and measurable disease.Xx_NEWLINE_xXPatients must have symptomatic multiple myeloma without advanced organ damage (such as multiple fractures or advanced bone disease causing immobilization, renal failure, spinal cord compression, or organ compromise due to soft tissue plasmacytoma); if immediate therapy with radiation and high-dose steroids (e.g., for spinal cord compression) or if triple therapy is clearly advisable from the start, the patient is not eligible for this trialXx_NEWLINE_xXParticipant has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (presence of serum M-protein <3 g/dL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the M-protein), or smoldering multiple myeloma (asymptomatic multiple myeloma with absence of related organ or tissue impairment end organ damage)Xx_NEWLINE_xXDiagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG] ).Xx_NEWLINE_xXMust have achieved at least a minimal response (MR) to at least 1 prior anti-myeloma regimen before developing PD (relapsed)Xx_NEWLINE_xXHas non-secretory multiple myelomaXx_NEWLINE_xXHas a confirmed diagnosis of active multiple myeloma and measurable diseaseXx_NEWLINE_xXClinically overt multiple myeloma, according to the International Myeloma Working Group (IMWG) criteria with at least 1 of the following:Xx_NEWLINE_xXmultiple myeloma (MM)Xx_NEWLINE_xX-  Documented relapsed or progressive Multiple Myeloma (MM) on or after any regimen or is refractory to the most recent line of therapy.Xx_NEWLINE_xXMeasurable disease on Screening per International Myeloma Working Group (IMWG) criteria.Xx_NEWLINE_xXSubject must have documented diagnosis with previously untreated (for cohort C, the induction and consolidation treatment along with the first Autologous stem cell transplantation (ASCT) are allowed), symptomatic Multiple Myeloma (MM) as defined by the criteria below:Xx_NEWLINE_xXAny one or more of the following myeloma defining events:Xx_NEWLINE_xXone or more of the following Myeloma-related organ dysfunction (at least one of the following);Xx_NEWLINE_xXPatient has been previously diagnosed with multiple myeloma (MM) based on standard criteria and currently requires treatment because MM has relapsed following a response, according to International Myeloma Working Group (IMWG) criteria.Xx_NEWLINE_xXDocumented refractory or relapsed and refractory multiple myelomaXx_NEWLINE_xXHas a confirmed diagnosis of active multiple myeloma and measurable disease.Xx_NEWLINE_xXHas non-secretory or oligosecretory multiple myelomaXx_NEWLINE_xXPathologically documented,multiple myeloma relapsed or refractory progressive disease after at least 3 lines of therapy for multiple myeloma. Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g. bortezomib) and immunomodulatory drugs (e.g. lenalidomide).Xx_NEWLINE_xXMultiple myeloma with IgM subtypeXx_NEWLINE_xXConfirmed diagnosis of symptomatic multiple myeloma and measurable secretory diseaseXx_NEWLINE_xXDiagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesionsXx_NEWLINE_xXPrior or concurrent invasive malignancy (other than multiple myeloma) within 5 years of study startXx_NEWLINE_xXExhibiting clinical signs of meningeal involvement of multiple myelomaXx_NEWLINE_xXMultiple myeloma (MM), limited to those patients for whom standard curative or palliative treatments do not exist or are no longer effectiveXx_NEWLINE_xXPatient has a diagnosis of multiple myeloma with documented relapsed and/or relapsed-refractory diseaseXx_NEWLINE_xXFor Multiple Myeloma cohortXx_NEWLINE_xXHave a documented diagnosis of multiple myeloma and have relapsed and refractory disease.Xx_NEWLINE_xXPrimary refractory multiple myeloma defined as patients who have never achieved at least a minimal response (MR) with any treatment during the disease course.Xx_NEWLINE_xXParticipant has documented relapsed or progressive multiple myeloma on or after any regimen or who are refractory to the most recent line of therapy. Relapsed myeloma is defined as previously treated myeloma that progresses and requires initiation of salvage therapy, but does not meet the criteria for refractory myeloma. Refractory myeloma is defined as disease that is non responsive (failure to achieve minimal response or development of progressive disease [PD]) while on primary or salvage therapy, or progresses within 60 days of last therapy.Xx_NEWLINE_xXHistologically confirmed multiple myelomaXx_NEWLINE_xXFour or less prior lines of systemic therapy for multiple myelomaXx_NEWLINE_xXAll subjects must have documented disease progression per IMWG criteria during or after their last anti-myeloma therapy.Xx_NEWLINE_xXPatients with multiple primary cancersXx_NEWLINE_xXParticipants proven to have multiple myeloma (MM) diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteriaXx_NEWLINE_xXParticipant is exhibiting clinical signs of meningeal involvement of multiple myelomaXx_NEWLINE_xXNewly diagnosed or relapsed multiple myelomaXx_NEWLINE_xXFor newly diagnosed multiple myeloma: multiple myeloma of IgM subtypeXx_NEWLINE_xXDiagnosis of smoldering multiple myeloma (SMM) for less than 5 yearsXx_NEWLINE_xXActive multiple myeloma,requiring treatment as defined by the study protocolXx_NEWLINE_xXMust have had documented multiple myelomaXx_NEWLINE_xXMust have received at least 1 prior line of therapy for multiple myelomaXx_NEWLINE_xXMust have had documented evidence of progressive disease as defined based on Investigator's determination of response of International Myeloma Working Group (IMWG) criteria on or after their last regimenXx_NEWLINE_xXHas a history of malignancy (other than multiple myeloma) within 3 years before the date of randomizationXx_NEWLINE_xXSubjects of ? 18 years of age with histopathologically confirmed diagnosis of lymphoma or multiple myeloma that is refractory to or relapsed after at least 2 prior regimens.Xx_NEWLINE_xXPatients will be ineligible if they have advanced myeloma refractory to salvage chemotherapy regimensXx_NEWLINE_xXEvidence of a response (partial response [PR] or better based on investigator's determination of response by International Myeloma Working Group [IMWG] criteria) to at least 1 prior treatment regimenXx_NEWLINE_xXDocumented measurable disease for multiple myeloma at screening as defined in protocolXx_NEWLINE_xXClinical signs of meningeal involvement of multiple myelomaXx_NEWLINE_xXPatients who at initial diagnosis or later met the International Myeloma Working Group (IMWG) definition of active multiple myeloma requiring therapy (Appendix 3)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed smoldering multiple myeloma confirmed by Department of Pathology, based on the International Myeloma Working Group CriteriaXx_NEWLINE_xXPatients with a diagnosis of multiple myeloma (MM) per standard International Myeloma Working Group (IMWG) criteriaXx_NEWLINE_xXPrior or concurrent systemic treatment for SMM; a) bisphosphonates are permitted; b) treatment with corticosteroids is not permitted; c) radiotherapy is not permitted; d) prior treatment for smoldering multiple myeloma with chemotherapy agents approved for the treatment of multiple myeloma is not permittedXx_NEWLINE_xXParticipants must have a diagnosis of multiple myeloma (MM) according Revised International Myeloma Working Group diagnostic criteria:Xx_NEWLINE_xXRelapsed multiple myelomaXx_NEWLINE_xXRefractory multiple myeloma defined as meeting 1 or more of the following:Xx_NEWLINE_xXAt least 2 but no more than 3 prior therapies for multiple myelomaXx_NEWLINE_xXMultiple myeloma of Immunoglobin M (IgM) subtypeXx_NEWLINE_xXConfirmed diagnosis of relapsed and/or refractory multiple myeloma (MM) according to International Myeloma Working Group guidelines (2003); refractory disease is defined as documented disease progression during or within 60 days after their most recent line of anti-myeloma therapyXx_NEWLINE_xXSymptomatic multiple myeloma or any evidence of CRAB criteria including the new criteria for overt myeloma; any prior therapy for active myeloma should also be excluded; prior therapy for smoldering myeloma is not an exclusion criterion; bisphosphonates are not excludedXx_NEWLINE_xXNew diagnosis of multiple myeloma with no prior history of treatment (exceptions include corticosteroids, bisphosphonates, single agent cyclophosphamide, =< 21 days of the first cycle of a planned regimen)Xx_NEWLINE_xXHistory of previously treated smoldering myelomaXx_NEWLINE_xXParticipant has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering multiple myelomaXx_NEWLINE_xXPatients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies, which must include lenalidomide and a proteasome inhibitor; patients must have disease refractory to the most recent therapy; refractory myeloma is defined as progressive disease during or within 60 days of last therapy; patients must have previously received or be ineligible for (or refused) autologous stem cell transplantXx_NEWLINE_xXAdult male or female participants 18 years or older with a confirmed diagnosis of symptomatic multiple myeloma according to standard criteria.Xx_NEWLINE_xXMultiple myeloma which has relapsed following primary therapy or is not responsive to primary therapy. For this study, stable disease following ASCT will be considered nonresponsive to primary therapy.Xx_NEWLINE_xXPatients must have a history of symptomatic multiple myeloma according to the International Myeloma Working Group criteria (IMWG, 2003)Xx_NEWLINE_xXPatient has relapsed or relapsed/refractory multiple myeloma (MM);\r\n* Relapsed is defined as the development of disease progression following the achievement of stable disease (SD) or better to the most recent anti-MM regimen\r\n* Refractory is defined as experiencing less than a partial response (PR) to or progressive disease (PD) within 6 months after completion of the most recent anti-MM regimenXx_NEWLINE_xXPatient has exquisitely radiosensitive histology, such as multiple myeloma, lymphoma, leukemia, or seminomaXx_NEWLINE_xXPatients must have a diagnosis of relapsed or relapsed and refractory multiple myeloma with a minimum of one prior regimen and a maximum of 5 prior regimensXx_NEWLINE_xXMust have documented multiple myeloma and measurable diseaseXx_NEWLINE_xXMust have received at least 1 prior line of therapy for multiple myeloma and achieved a response (partial response or better) to at least one prior regimenXx_NEWLINE_xXMust have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimenXx_NEWLINE_xXMultiple myeloma that is primary refractory or relapsed and refractory after at least 2 lines of standard for multiple myeloma including: a. > 2 consecutive cycles of both bortezomib and lenalidomide or thalidomide (alone or in combination) i. Patients who received bortezomib as their last therapy who were not refractory but developed bortezomib intolerance, as defined by the development of Grade 2 peripheral neuropathy with pain or > Grade 3 peripheral neuropathy after ? 2 consecutive cycles, are eligible b. Adequate alkylator therapy defined as: i. High-dose melphalan or other alkylating agent as conditioning for autologous or allogeneic stem cell transplant (SCT), or ii. ? 6 cycles of induction therapy, or iii. PD after ? 2 cyclesXx_NEWLINE_xXMust have a documented diagnosis of multiple myeloma and have relapsed-and-refractory disease. Patients must have received at least 2 lines of prior therapies. Patients must have relapsed after having achieved at least stable disease (SD) for at least one cycle of treatment to at least one prior regimen and then developed progressive disease (PD). Patients must also have documented evidence of PD during or within 60 days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry (refractory disease)Xx_NEWLINE_xXParticipants must have a previous diagnosis of MM, according to International Myeloma Foundation 2003 diagnostic criteriaXx_NEWLINE_xXHistologic confirmation of multiple myeloma by the enrolling institutionXx_NEWLINE_xXSymptomatic myeloma that has progressed/relapsed after 1 to 3 prior lines of therapyXx_NEWLINE_xXPatients with a diagnosis of multiple myeloma (MM) not achieving a VGPR or better to the most recent therapy.Xx_NEWLINE_xXPatients receiving > 1 cycle of prior treatment or concurrent systemic treatment for multiple myeloma\r\n* Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted\r\n* Bisphosphonates are permitted\r\n* Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted\r\n* Prior treatment with radiotherapy is permitted\r\n* Prior treatment for smoldering myeloma is permitted with a washout period of 2 weeks from last dose; smoldering patients previously treated with carfilzomib are excluded\r\n* Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 2 weeks from last dose (on a trial or outside a trial) are eligibleXx_NEWLINE_xXRelapsed or refractory multiple myeloma and has already received =< 4 standard treatment regimens; note: induction, transplant, consolidation, and maintenance is considered one regimenXx_NEWLINE_xXPatients must have a diagnosis of myeloma (see Appendix A for diagnostic criteria).Xx_NEWLINE_xXPatients must have progressive or active disease following prior therapy for their myeloma which:Xx_NEWLINE_xXPrior treatment for multiple myeloma with either standard of care treatment or investigational regimenXx_NEWLINE_xXParticipants must have had a diagnosis of symptomatic multiple myeloma (MM), MM + amyloidosis, or POEMS (osteosclerotic myeloma: polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) requiring treatment; participants with a previous history of smoldering myeloma will be eligible if there is evidence of progressive disease requiring chemotherapy; note that study participants do not need to have active disease at the time of study entry, as participants may have received up to 12 months of prior chemotherapy, which might have induced a responseXx_NEWLINE_xXDiagnosis of multiple myeloma with measureable diseaseXx_NEWLINE_xXPatients requiring therapy who have relapsed and/or are refractory to their last therapy and have been treated with at least 1, but not more than 5 lines of multiple myeloma therapy.Xx_NEWLINE_xXNewly diagnosed, myeloma requiring systemic chemotherapy as per International Myeloma Working Group (IMWG) uniform criteria:\r\n* Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids or lenalidomide or bortezomib-based regimens does not disqualify the patient (the treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle)\r\n* Bisphosphonates are permittedXx_NEWLINE_xXWaldenstrom's macroglobulinemia or immunoglobulin (Ig)M myelomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed relapsed multiple myeloma as defined by the International Myeloma Working Group (IMWG)Xx_NEWLINE_xXMust have documented diagnosis of multiple myeloma and have measureable disease by serum and urine protein electrophoresis.Xx_NEWLINE_xXMust have had at least 1 but no greater than 3 prior anti-myeloma regimens.Xx_NEWLINE_xXMust have documented disease progression during or after their last anti-myeloma therapy.Xx_NEWLINE_xXNon-secretory multiple myeloma.Xx_NEWLINE_xXSymptomatic multiple myeloma;Xx_NEWLINE_xXDiagnosis of active Multiple Myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteriaXx_NEWLINE_xXRelapsed or relapsed/refractory progressive Multiple MyelomaXx_NEWLINE_xXPatient with radiosensitive histologies (lymphoma, multiple myeloma, small cell carcinomas, germ cell tumors)Xx_NEWLINE_xX(Part 1) Have relapsed multiple myeloma after receiving a minimum of 2 and a maximum of 4 prior lines of therapy and be eligible for treatment with lenalidomide and dexamethasone (Len/Dex)Xx_NEWLINE_xX(Part 2) Have received at least 1 prior line of therapy for multiple myelomaXx_NEWLINE_xXRecovered from the effects of any prior systemic therapy or radiotherapy for Multiple MyelomaXx_NEWLINE_xXNon-secretory or oligo-secretory Multiple Myeloma (Phase II only; such disease is permissible in Phase I).Xx_NEWLINE_xXMultiple myeloma diagnosed according to standard criteria either currently or at the time of initial diagnosis. NOTE: The initial diagnosis must have been symptomatic multiple myeloma, although the relapsed disease did not need to be symptomatic.Xx_NEWLINE_xXDiagnosis of smoldering multiple myeloma (SMM) for <4 yearsXx_NEWLINE_xXHaving symptomatic multiple myeloma, defined by any of the following (if due to myeloma): lytic bone lesions, severe osteopenia (low bone density), pathologic fractures, hypercalcemia (too much calcium in the blood), kidney insufficiency; symptomatic hyperviscosity of the blood, or recurrent serious bacterial infections such as pneumoniaXx_NEWLINE_xXConfirmed diagnosis of multiple myeloma that is relapsed and/or refractory for which no curative option exists.Xx_NEWLINE_xXPatient must not have been previously treated with any prior systemic therapy for the treatment of active multiple myeloma\r\n* Prior treatment of hypercalcemia or spinal cord compression with corticosteroids does not disqualify the patient (the dose should not exceed the equivalent of 320 mg of dexamethasone in a 2 week period)\r\n* Bisphosphonates are permitted\r\n* Prior therapy for smoldering myeloma is permittedXx_NEWLINE_xXPatients with relapsed multiple myeloma who have already received one or more standard treatment regimensXx_NEWLINE_xXPreviously diagnosed with multiple myeloma.Xx_NEWLINE_xXPatients meeting the criteria for symptomatic multiple myeloma (MM):\r\n* Lytic lesions on skeletal survey or\r\n* Plasmacytoma\r\nPatients meeting International Myeloma Working Group definition of symptomatic myeloma with symptoms only related to associated amyloidosis who would otherwise only meet the criteria for smoldering MM are potentially eligibleXx_NEWLINE_xXA histologically established diagnosis of multiple myeloma with evidence of relapse or refractory disease.Xx_NEWLINE_xXRefractory or relapsed multiple myelomaXx_NEWLINE_xXConfirmed diagnosis of multiple myelomaXx_NEWLINE_xXPatient must have multiple myeloma that has either relapsed or has high risk cytogeneticsXx_NEWLINE_xXPatients receiving > 1 cycle of prior treatment or concurrent systemic treatment for multiple myeloma\r\n* Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted\r\n* Bisphosphonates are permitted\r\n* Concurrent or prior treatment with corticosteroids for indications other than multiple myeloma is permitted\r\n* Prior treatment with radiotherapy is permitted\r\n* Prior treatment for smoldering myeloma is permitted with a washout period of 4 weeks from last dose; smoldering patients previously treated with carfilzomib are excluded\r\n* Patients with measurable disease who received up to one cycle of any therapy within 60 days with a washout period of 4 weeks from last dose (on a trial or outside a trial) are eligibleXx_NEWLINE_xXMSKCC confirmed diagnosis of multiple myeloma that has relapsed or is resistant after therapy with at least one immunomodulatory drug (i.e. lenalidomide, thalidomide) and at least one proteasome inhibitorXx_NEWLINE_xXPatients with multiple myeloma who are potential candidates for high dose chemotherapy with stem cell rescueXx_NEWLINE_xXThe primary tumor is small-cell lung cancer, lymphoma, leukemia, or multiple myelomaXx_NEWLINE_xXMust have received 1-5 prior therapies for their myeloma and have relapsed or refractory multiple myeloma; prior therapy with bortezomib is allowed as long as they were not refractory to bortezomibXx_NEWLINE_xXHistologic and serologic findings from Memorial Sloan-Kettering Cancer Center (MSKCC) confirming the diagnosis of multiple myeloma; standard diagnostic criteria for multiple myeloma will be used, as per the revised International Myeloma Working Group diagnostic criteriaXx_NEWLINE_xXPatients must have symptomatic multiple myeloma without advanced organ damage (such as multiple fractures or advanced bone disease causing immobilization, renal failure, spinal cord compression, or organ compromise due to soft tissue plasmacytoma); if immediate therapy with radiation and high-dose steroids (e.g., for cord compression) or with bortezomib-based therapy (e.g., for renal failure) is required, the patient is not eligible for this trialXx_NEWLINE_xXPatients may have received 1 cycle of prior therapy with dexamethasone for multiple myelomaXx_NEWLINE_xXPrior treatment for myeloma except for one cycle of dexamethasoneXx_NEWLINE_xXGroup A: Metastatic disease, myeloma, lymphoma;Xx_NEWLINE_xXMultiple myeloma\r\n* Relapse/progression after autologous HSCT\r\n* Plasma cell leukemia\r\n* Adverse cytogenetics: del(13q) or 11q translocationXx_NEWLINE_xXMultiple myeloma: stage II or III, symptomatic, secretory multiple myeloma requiring treatmentXx_NEWLINE_xXMeets diagnostic criteria for symptomatic multiple myelomaXx_NEWLINE_xXLesions due to hematologic malignancy (e.g. multiple myeloma at site of the index vertebra (e),Xx_NEWLINE_xXSymptomatic multiple myeloma by International Myeloma Working Group (IMWG) criteria according to the most recent updated version (International Myeloma Workshop [IMW] meeting in Paris 2011)Xx_NEWLINE_xXMust meet any of these criteria for high risk disease:\r\n* Relapse or progressive disease according to uniform response criteria within 2 years after starting first-line therapy or within 2 years after autologous stem cell transplant\r\n* Failure to achieve partial response (PR) within 6 months of staring first-line therapy\r\n* Presence of high risk cytogenetic features (t[14;16], t[14;20], deletion 17p)\r\n* Chromosome 14 translocations other than to chromosome 11\r\n* Chromosome 1p deletion and 1q amplification\r\n* Myeloma Prognostic Risk Score (MyPRS) gene expression score equal or higher than 45.2\r\n* High risk 70 gene expression profile (MyPRS GEP70^TM)\r\n* Any other high risk genetic profile that is determined by future IMWG consensus or by internal myeloma panel consensus; for the latter, any additional criteria will be submitted as an addendum\r\n* Diagnosed with multiple myeloma between the ages of 18-50Xx_NEWLINE_xXMust have a documented diagnosis of relapsed and refractory multiple myeloma defined by the International Myeloma Working Group (IMWG) criteria.Xx_NEWLINE_xXPatients with a diagnosis of leukemia, lymphoma, or myelomaXx_NEWLINE_xXPatients with plasma cell myeloma treated with induction therapy or re-induction therapy, who at the time of study enrollment have documented evidence of stable disease response or better according to International Myeloma Workshop Consensus PanelXx_NEWLINE_xXPatients with progressive or refractory plasma cell myeloma, as defined by International Myeloma Workshop Consensus Panel criteriaXx_NEWLINE_xXDiagnosed with previously treated multiple myeloma.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of multiple myeloma that has progressed despite at least one line of standard therapyXx_NEWLINE_xXMeets the International Myeloma Working Group (IMWG) definition of Multiple MyelomaXx_NEWLINE_xXTreatment Group C (TGC): Multiple myelomaXx_NEWLINE_xXConfirmed diagnosis of multiple myeloma with a BRAF V600 mutationXx_NEWLINE_xXMust have received at least one prior systemic therapy for the treatment of multiple myelomaXx_NEWLINE_xXMust have relapsed and/or refractory multiple myeloma with measurable diseaseXx_NEWLINE_xXMelanoma, papillary thyroid cancer or hematological malignancies (with the exception of multiple myeloma)Xx_NEWLINE_xXMultiple myeloma: solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasiaXx_NEWLINE_xXPatients previously diagnosed with multiple myelomaXx_NEWLINE_xXPatients must have relapsed or relapsed and refractory multiple myeloma (MM) after at least three but not more than six prior therapeutic regimens for MM, including induction therapy and stem cell transplant in candidate patients, which will be considered as only one regimen.Xx_NEWLINE_xXDiagnosis of multiple myelomaXx_NEWLINE_xXThe first 3 patients on the experimental arm will be high risk myeloma and subsequent patients will be low risk myeloma; high risk multiple myeloma patient who have: deletion (del) 17p, del 1p, T (4;14), T (14;16), plasma cell leukemia (PCL), > 1 cytogenetic abnormality, hypodeploid; patients who fail adequate initial therapy (Revlimid, Velcade, dexamethasone [RVD], thalidomide, Velcade, dexamethasone [TVD], or cyclophosphamide, bortezomib, dexamethasone [CyBorD]) and planned to receive non-chemotherapy/cytotoxic salvage regimen (except for single agent cyclophosphamide)Xx_NEWLINE_xXNo more than six months’ worth of multiple myeloma chemotherapy is allowed (from the date of the start of the induction therapy)Xx_NEWLINE_xXDiagnosis of relapsed multiple myelomaXx_NEWLINE_xXFor more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subjects must have histological confirmation of multiple myeloma with measurable\n             disease (per International Myeloma Working Group (IMWG) criteria):\n\n               -  Relapsed/refractory multiple myeloma, subjects who are post autologous transplant\n                  and have achieved very good partial response (VGPR) or complete response (nCR)\n                  with minimal residual disease (MRD)Xx_NEWLINE_xXDiagnosis of multiple myeloma or non-Hodgkin lymphomaXx_NEWLINE_xXPatients with confirmed multiple myeloma whose treatment history must include all of the following:Xx_NEWLINE_xXMeasurable multiple myeloma disease, defined as meeting at least one of the following criteria within 14 days prior to first dose of study drug:Xx_NEWLINE_xXPrimary amyloidosis (amyloidosis associated with multiple myeloma is allowed).Xx_NEWLINE_xXPatients with relapsed/refractory multiple myeloma based on standard criteriaXx_NEWLINE_xXConfirmed multiple myeloma with measurable disease.Xx_NEWLINE_xXDisease refractory to last myeloma regimen.Xx_NEWLINE_xXPrimary amyloidosis (amyloidosis associated with multiple myeloma is allowed).Xx_NEWLINE_xXPatients with any hematologic malignancy. This includes leukemia (any form), lymphoma, and multiple myeloma.Xx_NEWLINE_xXMemorial Sloan-Kettering Cancer Center (MSKCC) confirmed diagnosis of multiple myeloma that has relapsed or is resistant after therapy with at least one immunomodulatory drug (i.e. lenalidomide, thalidomide) and at least one proteasome inhibitorXx_NEWLINE_xXPatients with multiple myeloma (MM) diagnosed according to standard criteria or patients with a diagnosis of an advanced malignant solid tumor for which standard, curative, or life prolonging treatment does not exist or is no longer effective. Patients with multiple myeloma must have had at least 1 prior therapyXx_NEWLINE_xXPatients with relapsed/refractory multiple myeloma after at least 1 prior therapyXx_NEWLINE_xXNewly diagnosed symptomatic multiple myeloma (per International Myeloma Working Group [IMWG] diagnostic criteria)Xx_NEWLINE_xXNo prior treatment for multiple myelomaXx_NEWLINE_xXMultiple myeloma of IgM (immunoglobulin M) subtypeXx_NEWLINE_xXMultiple myelomaXx_NEWLINE_xXWilling to undergo pre-dose core needle tumor biopsies or bone marrow aspirate for subjects with multiple myeloma.Xx_NEWLINE_xXRelapsed or refractory Multiple Myeloma (MM) a. Treated with at least 1 prior regimen for myelomaXx_NEWLINE_xXDiagnosis of symptomatic MM as defined by the International Myeloma Working Group (IMWG) :Xx_NEWLINE_xXPatients with relapsed multiple myeloma who have already received one or more standard treatment regimensXx_NEWLINE_xXElevated Free Light Chain as per the International Myeloma Working Group (IMWG) criteriaXx_NEWLINE_xXPatients must have a history of symptomatic multiple myeloma according to the International Myeloma Working Group criteria (IMWG, 2003), as defined as the following three criteria:\r\n* Clonal plasma cells > 10% on bone marrow biopsy\r\n* A monoclonal protein (paraprotein) in either serum or urine (except in cases of non-secretory myeloma)\r\n* Evidence of end-organ damage felt related to the plasma cell disorder (related organ or tissue impairment, ROTI, commonly referred to by the acronym \calcium, renal failure, anemia, and bone lesions [CRAB]\):\r\n* Hypercalcemia serum calcium (Ca) >= 11.5 mg/dL or\r\n* Renal insufficiency attributable to myeloma; serum creatinine > 2mg/dL\r\n* Anemia: Normochromic, normocytic with a hemoglobin value > 2g/dL below the lower limit of normal or a hemoglobin < 10 g/dL\r\n* Bone lesions (lytic lesions, severe osteopenia or pathologic fractures)Xx_NEWLINE_xXPatient has relapsed or relapsed/refractory multiple myeloma (MM)\r\n* Relapsed is defined as the development of disease progression following the achievement of stable disease (SD) or better to the most recent anti-MM regimen\r\n* Refractory is defined as experiencing less than a partial response (PR) to or progressive disease (PD) within 6 months after completion of the most recent anti-MM regimenXx_NEWLINE_xXPatients with relapsed or refractory myeloma who have had >= 3 lines of prior therapyXx_NEWLINE_xXMultiple myeloma with relapsing or progressing disease at study entry.Xx_NEWLINE_xXPatients must have evaluable multiple myeloma with, at least one of the following (assessed within 21 days prior to randomization):Xx_NEWLINE_xXMultiple Myeloma of IgM subtype.Xx_NEWLINE_xXDiagnosis of relapsed or refractory multiple myeloma (MM) and documentation of at least 1 prior therapy; there is no maximum number of prior regimensXx_NEWLINE_xXMultiple myeloma (MM)Xx_NEWLINE_xXSubjects with Multiple Myeloma (MM) and renal function fitting one of three categories:Xx_NEWLINE_xXSymptomatic multiple myeloma or asymptomatic myeloma with myeloma-related organ damage diagnosed according to standard criteriaXx_NEWLINE_xXPrior systemic therapy for multiple myeloma, including investigational drugs (prior treatment with corticosteroids or localized radiation therapy dose not disqualify the patient)Xx_NEWLINE_xXIs diagnosed with symptomatic multiple myeloma or asymptomatic myeloma with myeloma-related organ damage according to standard criteriaXx_NEWLINE_xXHas prior systemic therapy for multiple myeloma, including investigational drugs (prior treatment with corticosteroids or localized radiation therapy dose not disqualify the participantt)Xx_NEWLINE_xXPatient has relapsed or relapsed/refractory MM with measurable disease parameters according to the International Myeloma Working Group (IMWG) CriteriaXx_NEWLINE_xXSubjects must have documented diagnosis of multiple myeloma and have measurable diseaseXx_NEWLINE_xXSubjects must have either refractory or relapsed and refractory disease defined as documented disease progression during or within 60 days of completing their last myeloma therapyXx_NEWLINE_xXPart A: Have histological or cytological evidence of cancer (solid tumor, lymphoma, or multiple myeloma) that is advanced and/or metastatic and an appropriate candidate for experimental therapyXx_NEWLINE_xXDocumentation of at least one line of prior myeloma therapy now with relapsed or refractory disease requiring re-treatmentXx_NEWLINE_xXUse of any anti-myeloma drug therapy within 14 days of initiation of study drug treatment excluding corticosteroids if given for an indication other than myeloma; note: bisphosphonates are not considered anti-myeloma drugsXx_NEWLINE_xXRelapsed multiple myeloma. At least ?1 line of therapy and progressed after ?1 prior therapyXx_NEWLINE_xXMultiple myeloma of IgM subtype, POEMS, plasma cell leukemiaXx_NEWLINE_xXMultiple myeloma of IgM subtype, POEMS, plasma cell leukemiaXx_NEWLINE_xXSymptomatic multiple myelomaXx_NEWLINE_xXPrior treatment with at least one, but no more than three, regimens for multiple myelomaXx_NEWLINE_xXWaldenström's macroglobulinemia or IgM myelomaXx_NEWLINE_xXPatients with poor prognosis multiple myeloma by cytogenetics (del13, del 17p, t(1;14) or t(14;16) or hypodiploidy, with advanced disease (stage >= 2) and/or relapsed after autologous stem cell transplantXx_NEWLINE_xXDiagnosis of AML, Multiple myeloma, Hodgkin's or Non-Hodgkin's lymphoma for whom standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXAge 18 years or older with a confirmed diagnosis of multiple myeloma (MM) and documentation of one to three prior therapies.Xx_NEWLINE_xXPreviously untreated, symptomatic multiple myeloma as defined by the 3 criteria below:Xx_NEWLINE_xXPrior history of malignancies, other than multiple myeloma, unless the patient has been free of the disease for ? 3 years. Exceptions include the following:Xx_NEWLINE_xX1 A variety of other types of end organ dysfunctions can occasionally occur and lead to a need for therapy. Such dysfunction is sufficient to support classification as myeloma if proven to be myeloma-related.Xx_NEWLINE_xXPatients must have a diagnosis of active multiple myelomaXx_NEWLINE_xXPatients with presence of multiple bladder lesionsXx_NEWLINE_xXPatients must have a definitive diagnosis of multiple myeloma (using the International Myeloma Working Group Guidelines)Xx_NEWLINE_xXPatients who have not received any chemotherapy treatment for multiple myeloma prior to being enrolled in the studyXx_NEWLINE_xXPatients who were receiving simvastatin (dose > 40 mg/day) while receiving current chemotherapy regimen for multiple myelomaXx_NEWLINE_xXMultiple myeloma that does not express M-protein or FLC (i.e., non-secretory MM is excluded), and quantitative immunoglobulin levels cannot be used instead.Xx_NEWLINE_xXPatients with multiple myeloma who have not achieved a complete remission (CR) following at least 4 cycles of induction therapyXx_NEWLINE_xXRelapsed/refractory myelomaXx_NEWLINE_xXParticipants must have histologically confirmed multiple myeloma that is relapsed or refractoryXx_NEWLINE_xXParticipants must have a diagnosis of relapsed multiple myeloma according to standard criteria established by the International Myeloma Working GroupXx_NEWLINE_xXPatients may have had 1 or more prior chemotherapy regimens for multiple myeloma but none within the preceding 14 daysXx_NEWLINE_xXPatients who are suffering from symptoms of bone metastases or multiple myeloma bone lesions:Xx_NEWLINE_xXPhase II: Myeloma diagnosisXx_NEWLINE_xXDiagnosis of cancer, not including multiple myeloma or lymphoma/leukemiaXx_NEWLINE_xXMultiple myeloma or plasma cell leukemia with a PR or better to the last treatment regimen, based on the International Myeloma Working Group (IMWG) criteriaXx_NEWLINE_xXDiagnosis of multiple myelomaXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed multiple myeloma, or non-Hodgkin lymphoma and must be undergoing melphalan conditioning for autologous HSCTXx_NEWLINE_xXHistologies of myeloma or lymphomaXx_NEWLINE_xXPatients with pathologically diagnosed who have received induction chemotherapy, with or without autologous stem cell transplantation (AuSCT), and who have qualified to receive lenalidomide-based maintenance therapy for their multiple myeloma (MM)Xx_NEWLINE_xXDocumented evidence of multiple myeloma (per local assessment):Xx_NEWLINE_xXDocumented diagnosis of multiple myeloma, currently with complete response (CR) or very good partial response (VGPR) (as defined by International Myeloma Working Group [IMWG] criteria), at least two years after induction therapy or autologous stem cell transplantXx_NEWLINE_xXDiagnosis of multiple myelomaXx_NEWLINE_xXHistory of multiple cancersXx_NEWLINE_xXLeukemia, lymphoma, and myelomaXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed diagnosis of solid tumor malignancy, lymphoma, or multiple myelomaXx_NEWLINE_xXHigh risk, or refractory and relapsed multiple myelomaXx_NEWLINE_xXMultiple myeloma in CR/very good partial response (VGPR)Xx_NEWLINE_xXMultiple myeloma (MM), requiring treatment, defined by any of the following:Xx_NEWLINE_xXMultiple myeloma meeting the following criteria:Xx_NEWLINE_xXPathologically-documented diagnosis of multiple myeloma that is relapsed or is refractory as defined by the following:Xx_NEWLINE_xXMultiple myeloma with IgM subtypeXx_NEWLINE_xXSubject has aplastic anemia or multiple myelomaXx_NEWLINE_xXPatients with multiple co-existing central venous catheters at the time of enrollment will not be enrolled; multiple lumens in a single catheter are acceptableXx_NEWLINE_xXDiagnosed with multiple myeloma and in complete, partial or very good partial remission at enrollment as per standard International Myeloma Working Group CriteriaXx_NEWLINE_xXHistologically confirmed multiple myeloma (newly diagnosed or relapsed); (Note: multiple myeloma patients with secondary amyloidosis are eligible)Xx_NEWLINE_xXPatients with the clinical diagnosis of multiple myeloma (MM) will be referred to MRI by hematologists/oncologists at New York University Medical Center (NYUMC) who care for these patientsXx_NEWLINE_xXA prior diagnosis of multiple myeloma with documented disease progressionXx_NEWLINE_xXPrevious cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within defined values prior to start of study treatmentXx_NEWLINE_xXSubject must have a pathologically documented, definitively diagnosed, multiple myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy for multiple myeloma. Prior therapeutic treatment or regimens must include a proteasome inhibitor and lenalidomide.Xx_NEWLINE_xXMultiple myeloma with IgM subtype.Xx_NEWLINE_xXHave history of paraproteinemias or multiple myelomaXx_NEWLINE_xXNORMAL VOLUNTEERS: Have history of paraproteinemias or multiple myelomaXx_NEWLINE_xXHas received previous myeloma-specific therapy.Xx_NEWLINE_xXDocumentation of r/r MM as defined by the International Myeloma Working Group (IMWG) criteria.Xx_NEWLINE_xXRelapsed multiple myelomaXx_NEWLINE_xXReceived at least 1 prior treatment regimen or line of therapy for multiple myelomaXx_NEWLINE_xXImmunoglobulin M (IgM) multiple myelomaXx_NEWLINE_xXDiagnosis of multiple myeloma with documented relapsed or refractory disease according to international Myeloma Working Group (IMWG) criteria, or relapsed/refractory plasma cell leukemiaXx_NEWLINE_xXPrevious treatments for multiple myeloma (MM) within 2 weeks of initiation of study treatmentXx_NEWLINE_xXHematologic malignancies or multiple myeloma.Xx_NEWLINE_xX